Back

Low seroprevalence of neutralizing antibodies to adeno-associated virus serotype 9 in preparation for MyPEAK-1 study of TN-201 for individuals with MYBPC3-associated hypertrophic cardiomyopathy

18 May 2025 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Myocarditis Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Natalia Paterson

Tenaya Therapeutics, South San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Predictive factors for genetic positive test in genetic myocarditis
Doctor A. Paldino (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Sex differences in adverse cardiac remodelling after acute myocarditis.
Doctor A. Aguiar Neves (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Exploring biomarker correlations with cardiac remodelling after acute myocarditis
Doctor A. Aguiar Neves (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Clinical presentation and outcome in patients with acute myocarditis: a report from a tertiary centre
Doctor M. Bjorkenstam (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Endomyocardial biopsy in DSP-encoded desmoplakin arrhythmogenic cardiomyopathy: a single center review
Doctor R. Coderre (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Myocarditis

The Event

Event poster

Heart Failure 2025

18 May 2025 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Gene editing for Danon disease
thumbnail
Congress Presentation
Genetic therapies in inherited cardiomyopathies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources